BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim Report for the period October – December 2025

Wed, Feb 18, 2026 08:00 CET

A transformative year with record financial results Events during the fourth quarter 2025 · Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US · Leqembi was approved in Brazil and Canada · Leqembi was approved for IV maintenance treatment in the United Kingdom · Eisai submitted application for subcutaneous initiation treatment with Leqembi in Japan · New Leqembi data presented at CTAD 2025 suggested potential to delay disease progression by up to 8.3 years with continuous

There are no items matching the current filter

There are no more items matching the current filter

About Us

Interim Report for the period October – December 2025

Subscribe

Media

Share

About Us

Interim Report for the period October – December 2025

Subscribe

Media